A California appeals court has ruled that a software company that provided a program to distribute drug information to pharmacy customers might be liable to a plaintiff who received truncated warnings about a drug’s risks.
Plaintiff Kathleen Hardin is now blind and has “permanent, severe and painful scarring” after taking antiepileptic and bipolar drug Lamotrigine and experiencing Stevens-Johnson syndrome and toxic epidermal necrolysis, which left the top layer of her skin dead and shedding, the court said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
